Research progress on androgen receptor in triple-negative breast carcinoma

doi:10.3969/j.issn.1007-3969.2016.05.020

China Oncology ›› 2016, Vol. 26 ›› Issue (5): 466-470.doi: 10.3969/j.issn.1007-3969.2016.05.020

Previous Articles Next Articles

Research progress on androgen receptor in triple-negative breast carcinoma

LIU Xiaoli, JIANG Da, CUI Yanzhi

Department of Medical Oncology, the 4th Hospital, Hebei Medical University, Shijiazhuang 050035, Hebei Province, China

Online:2016-05-30 Published:2016-06-23
Contact: JIANG Da E-mail: jiangda139@163.com

Abstract

Abstract: Triple-negative breast cancers (TNBC) comprise a heterogeneous group of tumors characterized by poor survival and lack of targeted therapeutics. In recent years, androgen receptor (AR) has been demonstrated to play an important role in the genesis and development of TNBC. There has been increased interest in the role of AR in TNBC and AR-targeting has been introduced as a novel therapeutic option for TNBC. This review offers an overview of the relationship between AR expression and TNBC, and provides insights into the novel drugs in the development for targeting this signaling pathway.

Key words: Triple-negative breast cancer, Androgen receptor, Expression

LIU Xiaoli, JIANG Da, CUI Yanzhi. Research progress on androgen receptor in triple-negative breast carcinoma[J]. China Oncology, 2016, 26(5): 466-470.

[1]	GONG Chao , CHEN Kui , ZHANG Dekun , XIE Jingfeng , WU Fanghua , HUANG Yudian , XUE Yuqin , WANG Liqun . Construction of a prediction model for metastasis in gastric cancer based on the weighted gene co-expression network analysis [J]. China Oncology, 2021, 31(8): 746-753.
[2]	LIU Bin , ZHENG Pengyuan , MI Yang , REN Feifei , GAO Shuang , LIU Chuan , LI Fazhan . Expression of LRP8 in gastric cancer and its significance in tumorigenesis [J]. China Oncology, 2021, 31(4): 285-293.
[3]	HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang . Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer [J]. China Oncology, 2021, 31(3): 221-226.
[4]	CHEN Yang , LIU Wei , LI Ruimin , WANG Qifeng , SHEN Xigang , TANG Wei . Radiogenomics: association between BI-RADS mammographic imaging features and the 21-gene recurrence score [J]. China Oncology, 2020, 30(7): 505-511.
[5]	JIANG Mengyi , LU Yanqiao , WANG Hongxia . Research progress and clinical significance of breast cancer heterogeneity [J]. China Oncology, 2020, 30(5): 394-400.
[6]	SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng . Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer [J]. China Oncology, 2020, 30(3): 186-191.
[7]	CAO Xiaoshan, CONG Binbin. The progress of treatment for triple-negative breast cancer in the era of precision medicine [J]. China Oncology, 2019, 29(12): 971-976.
[8]	ZHENG Xiaying, CHEN Junxia. Expression of circRNA hsa_circ_0005320 in triple-negative breast cancer and its effect on cell proliferation [J]. China Oncology, 2019, 29(11): 845-854.
[9]	ZHU Xiuzhi, CHEN Li, JI Lei, GAO Yu, WANG Zhonghua. Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors [J]. China Oncology, 2019, 29(11): 899-905.
[10]	YANG Rui, CHEN Junxia. Effects of circular RNA hsa_circ_0058514 on the development and progression of triple-negative breast cancer [J]. China Oncology, 2019, 29(1): 9-18.
[11]	LI Jiawei, SHI Zhaoting, HOU Yingmin, et al. Clinicopathological and immunohistochemical basis for sonographic characteristics of triple-negative invasive breast cancer [J]. China Oncology, 2019, 29(1): 37-44.
[12]	JI Peng, GONG Yue, DI Genhong. Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer [J]. China Oncology, 2018, 28(12): 928-934.
[13]	LIU Zimei, YU Wenxi, SUN Chu, et al. Clinical significance of ICAM-1 expression and its correlation with prognosis of triple-negative breast cancer [J]. China Oncology, 2017, 27(2): 121-127.
[14]	SONG Yang, LIU Liyang, LI Fenghu, et al. Expression of HER-2 in 720 cases of breast cancer patients in Guizhou province and retrospective analysis of anti-HER-2 treatment [J]. China Oncology, 2017, 27(11): 884-889.
[15]	LIN Ying, YAN Yan, WU Zheng, et al. Correlation between mRNA expression of protocadherin-10 and prognosis in gastric cancer [J]. China Oncology, 2017, 27(1): 7-13.

Research progress on androgen receptor in triple-negative breast carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments